The management of patients with brain metastases has become a major issue due to the
increasing frequency and complexity of the diagnostic and therapeutic approaches. In 2014 …

The incidence of brain metastases has markedly increased in the past 20 years owing to
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …

Background: The analysis of the BRAF mutational status has been established as a
standard procedure during diagnosis of advanced malignant melanoma due to the fact that …

OBJECTIVE Melanoma represents the third most common cause of CNS metastases.
Immunotherapy has evolved as a treatment option for patients with Stage IV melanoma …

Malignant melanoma is the third most common type of tumor that causes brain metastases.
Patients with cerebral involvement have a dismal prognosis and their treatment is an unmet …

Background Targeted therapies (TT) and immune checkpoint inhibitors (ICI) are currently
modifying the landscape of metastatic cancer management and are increasingly used over …

Background Intracranial activity of lapatinib has been demonstrated in several studies in
patients with human epidermal growth factor receptor-2 positive breast cancers (HER-2+ …

Simple Summary In the multi-modal treatment of brain metastasis (BM), the role of systemic
therapy has undergone a recent revolution. Due to the development of multiple agents with …

Targeted therapy for oncogenic genetic alterations has changed the treatment paradigm of
advanced non-small cell lung cancer (NSCLC). Mutations in the BRAF gene are detected in …

Background Few safety data of concurrent stereotactic radiosurgery and targeted therapy
(TT) or immunotherapy (IT) are available. The aim of the study was to evaluate the outcome …